subscribeSubscribe
Merck KGaA suffers major blow as MS drug fails in late-stage trials

Merck KGaA suffers major blow as MS drug fails in late-stage trials
Ludwig Burger REUTERS
06 Dec 2023
Share Share
Merck KGaA`s MS drug passes durability test ahead of ph. 3 data

Merck KGaA`s MS drug passes durability test ahead of ph. 3 data
Nick Paul Taylor FIERCE BIOTECH
12 Oct 2023
Share Share
Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit

Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit
BUSINESSWIRE
11 Oct 2023
Share Share
Merck KGaA`s BTK inhibitor hit by partial clinical hold over safety concern

Merck KGaA`s BTK inhibitor hit by partial clinical hold over safety concern
Amber Tong ENDPTS
13 Apr 2023
Share Share
Initiation of New Patients on Evobrutinib Paused in the U.S.

Initiation of New Patients on Evobrutinib Paused in the U.S.
BUSINESSWIRE
12 Apr 2023
Share Share
Merck Highlights New Four-Year Efficacy and Safety Data for Evobrutinib

Merck Highlights New Four-Year Efficacy and Safety Data for Evobrutinib
BUSINESSWIRE
23 Feb 2023
Share Share
Merck Highlights New Data for Evobrutinib

Merck Highlights New Data for Evobrutinib
BUSINESSWIRE
26 Oct 2022
Share Share
EMD Serono Highlights New Data for Evobrutinib

EMD Serono Highlights New Data for Evobrutinib
BUSINESSWIRE
26 Oct 2022
Share Share
Merck KGaA showcases durability of evobrutinib in MS

Merck KGaA showcases durability of evobrutinib in MS
Nick Paul Taylor FIERCEBIOTECH
26 Oct 2022
Share Share
Data: Evobrutinib Demonstrates a Significant Reduction in SEL with RMS

Data: Evobrutinib Demonstrates a Significant Reduction in SEL with RMS
BUSINESSWIRE
14 Oct 2021
Share Share